tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Aprea Therapeutics files to sell 5.5M shares of common stock for holders
PremiumThe FlyAprea Therapeutics files to sell 5.5M shares of common stock for holders
2M ago
Advancing APR-1051 in HPV-Positive Cancers and Extended Cash Runway Underpin Aprea Therapeutics Buy Rating and $5 Target
Premium
Ratings
Advancing APR-1051 in HPV-Positive Cancers and Extended Cash Runway Underpin Aprea Therapeutics Buy Rating and $5 Target
2M ago
Aprea Therapeutics price target lowered to $5 from $20 at H.C. Wainwright
Premium
The Fly
Aprea Therapeutics price target lowered to $5 from $20 at H.C. Wainwright
2M ago
Aprea Therapeutics Reports Ongoing Financial Challenges
PremiumCompany AnnouncementsAprea Therapeutics Reports Ongoing Financial Challenges
3M ago
Aprea Therapeutics Reports Q3 Results and Clinical Updates
Premium
Company Announcements
Aprea Therapeutics Reports Q3 Results and Clinical Updates
3M ago
Aprea Therapeutics reports Q3 EPS (47c) vs. (64) last year
Premium
The Fly
Aprea Therapeutics reports Q3 EPS (47c) vs. (64) last year
3M ago
Aprea Therapeutics provides update from ACESOT-1051 t rial
PremiumThe FlyAprea Therapeutics provides update from ACESOT-1051 t rial
3M ago
Aprea Therapeutics: Strategic Advancements and Unique Positioning Drive Buy Recommendation
Premium
Ratings
Aprea Therapeutics: Strategic Advancements and Unique Positioning Drive Buy Recommendation
4M ago
Aprea Therapeutics Shifts Focus to Combination Therapies
Premium
Company Announcements
Aprea Therapeutics Shifts Focus to Combination Therapies
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100